CA-NETAPP
14.5.2024 14:02:00 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced NetApp AIPod with Lenovo ThinkSystem servers for NVIDIA OVX, a converged infrastructure optimized for the generative AI era. NetApp and Lenovo have had a strong partnership for over five years and are now taking the partnership to the next level with the introduction of this simple, cost-effective, and powerful solution for enterprise AI. The new converged infrastructure solution will support NVIDIA NIM inference microservices, the NVIDIA AI Enterprise software platform for generative AI development and deployment, and retrieval-augmented generation (RAG) to enable customers to leverage their private, proprietary data for AI without large-scale model training.
Generative AI has created extensive opportunities for organizations, though many may feel as if AI is out of reach due to the cost, integration complexity, and time to deployment. Meanwhile, pre-built large language models (LLMs) often do not have training on the most up-to-date or relevant data organizations need to generate valuable insights or effectively automate routine tasks.
NetApp has led in unstructured data storage for over three decades, and much of the world’s enterprise unstructured data is stored in NetApp storage. Unlocking the full value of this data requires going far beyond foundational model training. By enabling inferencing and RAG, the NetApp AIPod with Lenovo’s leading server reliability, quality, and performance makes it seamless, simple, and fast to combine the power of LLMs with precise, up-to-date, and pertinent information on NetApp storage.
"The NetApp AIPod with Lenovo ThinkSystem servers for NVIDIA OVX transforms enterprise AI by delivering a pre-integrated, high-performance solution that accelerates the deployment and scaling of generative AI workloads," said Sandeep Singh, Senior Vice President & General Manager, Enterprise Storage at NetApp. "Through our collaboration with NVIDIA and Lenovo, NetApp is empowering organizations to harness the capabilities of AI more efficiently, ensuring that they can focus on creating value and gaining insights from their data without the complexity of building and managing AI infrastructure from scratch."
NetApp AIPod combines NetApp's robust storage systems with hybrid cloud data management, including Lenovo's high-performance ThinkSystem SR675 V3 servers, the leading platforms supporting NVIDIA-certified OVX architecture with NVIDIA L40S GPUs, as well as NVIDIA Spectrum-X Networking, providing a complete and seamless infrastructure solution to streamline AI adoption. Using this solution, customers will be able to conduct AI RAG and inferencing operations for use cases like chatbots, knowledge management, and object recognition. NetApp, in collaboration with Lenovo and NVIDIA, simplifies AI deployment by seamlessly integrating into ecosystems, simplifying operations, accelerating implementation, and safeguarding AI infrastructure, enabling organizations to unlock AI's full potential.
“Lenovo is expanding our partnership with NetApp and NVIDIA to bring the power of AI to every business as part of our continued commitment to enabling and simplifying hybrid AI for our joint customers,” said Kirk Skaugen, President of Lenovo Infrastructure Solutions Group. “As customers deploy AI, they demand business critical availability, ease of management, and infrastructure efficiency. The NetApp AIPod with Lenovo ThinkSystem servers for NVIDIA OVX delivers optimized and validated solutions to make generative AI more accessible for businesses of every size.”
“Making AI accessible and scalable for every industry is more important than ever,” said Bob Pette, Vice President of Enterprise Platforms at NVIDIA. “The NetApp AIPod with Lenovo for NVIDIA OVX offers an AI-ready platform that’s powerful and easy to use, enabling businesses to drive innovation.”
NetApp AIPod with Lenovo for NVIDIA OVX will be available by summer 2024.
Additional Resources
- NetApp AIPodTM with Lenovo for NVIDIA OVX: The Power of Retrieval-Augmented Generation for Every Enterprise
- NetApp Unveils Unified Data Storage Built for the AI Era
- AIPod: Delivering the Promise
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability, and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514466001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
